Skip to main content

Table 8 Base case analysis results

From: Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

 

Glargine

NPH

Incremental

Mean (SD)

CI (low–high)

Mean (SD)

CI (low–high)

Mean

CI (low–high)

LE (years)

13.522 (0.165)

13.512–13.532

13.512 (0.16)

13.502–13.522

0.01

− 0.004 to 0.024

Undiscounted LE (years)

18.763 (0.28)

18.745–18.78

18.746 (0.271)

18.729–18.763

0.017

–

QALY

7.842 (0.105)

7.835–7.848

7.625 (0.104)

7.619–7.632

0.217

0.207–0.226

Undiscounted QALY (years)

10.651 (0.17)

10.641–10.662

10.347 (0.166)

10.337–10.357

0.304

–

Direct costs

701,015 (40,687)

698,493–703,536

678,641 (40,745)

676,115–681,166

22,373

18,726–26,021

Indirect costs

61,121 (6847)

60,697–61,546

62,135 (6637)

61,723–62,546

− 1013

− 1013 to − 1609

Combined costs

762,136 (47,535)

759,190–765,083

740,776 (47,382)

737,839–743,713

21,360

21,360–17,747

ICER

    

98,663

78,527–120,646

  1. Values are expressed as mean (standard deviation)
  2. HKD Hong Kong Dollar, ICER incremental cost-effectiveness ratio, LE life expectancy, LYG life year gained, QALY quality-adjusted life year